Overcoming Pharmaceutical Formulation Challenges – Webcasts by Fuji Chemicals
In drug development here is no one-size-fits-all approach which can be applied to allactive pharmaceutical ingredients (APIs). The best formulations and solutions depend on many characteristics, including the API characteristics, route of administration and delivery profile required. In order to solve the most challenging formulations, having the availability of a broad range of high-end multi-functional excipients is gives formulators a superior toolbox to develop successful and robust formulations.
On the 23rd and 24th of June 2020, Fuji will hold webcasts to introduce the following four product families. The key highlights for each are summarized here:
Webcasts on Fujicalin® & Neusilin®
Fuji Excipient Webcast June 23 Asia Pacific (14:30 JST)
11:00 IST; 13:30 CST
Register here
Fuji Excipient Webcast June 23 Europe (10:00 CEST) – Fujicalin & Neusilin
Register here
Fujicalin®: Non-abrasive porous DCPA for the versatile applications such as for probiotic tablet compression, black spots prevention in tablet compression and cushioning excipient for MUPS tablet by utilizing its unique plasticity and cushioning property.
Neusilin®: Multi-functional excipient for pharmaceutical applications, Neusilin®can improve tabletability and stability thru its superior flowability, compressibility and moisture protection capabilities.
Webcasts on F-MELT® & FujiSil®
Fuji Excipient Webcast June 24 Asia Pacific (14:30 JST)
11:00 IST; 13:30 CST
Register here
Fuji Excipient Webcast June 24 Europe (10:00 CEST)
Register here
F-Melt® : Co-processed excipients are generally required to meet the stringent dissolution times and mouthfeel needed for ODT’s. An independent study by GSK and UCL compares commercially available co-processed excipients for ODT’s and demonstrates the case for F-Melt®.
FujiSil®: Next generation highly porous silica for Oil adsorption, improvement of Tableting process and solubility enhancement application